Annals of the Rheumatic Diseases (ARD)

is a leading rheumatology journal from EULAR, publishing original research, reviews and recommendations

Impact Factor: 27.4
Citescore: 32.8
All metrics >>

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via Twitter and Facebook.

Listen to the ARD Podcast and subscribe in all podcast platforms, including Apple Podcasts, Amazon Music and Spotify.
NEW episode available now: 'A non-pharma approach in systemic lupus erythematosus and systemic sclerosis'

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Current Issue

Latest EULAR Recommendations

Management of systemic lupus erythematosus

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

The use of imaging in large vessel vasculitis in clinical practice

EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update

Early stages of diagnosis and management of suspected HLH/MAS

2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome

3D rendered photo of rheumatological disease affecting the hand

Non-pharmacological management of SLE and SSc

EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.

The Author Information section provides general guidelines and requirements for specific article types.

Information is also provided on editorial policies and open access.

Author information Submit a paper

Editor's Choice

Spondyloarthritis:

HLA-B27, axial spondyloarthritis and survival

7 September 2023

Rheumatoid arthritis:

Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study

24 July 2023

Rheumatoid arthritis:

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

9 July 2023

Review:

Approach to vaccination in systemic lupus erythematosus on biological treatment

19 June 2023

Latest Articles

Vasculitis:

Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasus arteritis, ANCA-associated vasculitis and giant cell arteritis

29 November 2023

Images in rheumatology:

Vasculitis that did not read the books

28 November 2023

Rheumatoid arthritis:

In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation

27 November 2023

Early arthritis:

Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres

27 November 2023

Rheumatoid arthritis:

Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis

24 November 2023

Articles by Topic

View full list

Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

All EULAR recommendations are free to access.

Each recommendation also has an accompanying lay summary, which is also free to access.

Video

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

10 October 2023

Conclusion: At Week 52, dual inhibition of IL-17A and IL-17F with BKZ resulted in sustained efficacy across the axSpA spectrum; the safety profile was consistent with the known safety of BKZ.

Find out more